PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.…
PTC Therapeutics Sees $2 Billion-Plus Sephience Potential, Sets January Guidance Date
PTC Therapeutics (NASDAQ: PTCT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 991 employees.
The shares were at 56.42 USD on 20 November 2026, down 22.3% over 52 weeks. Its 52-week range is 56.18 USD to 90.86 USD, and it trades at the bottom of that range.
Its market capitalisation is 4.71B USD.
PTC Therapeutics reports return on equity of -332.5%, an operating margin of 21.5% and revenue up 69.6% year over year.
Its debt exceeds its cash by 813.72M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 15 analysts cover the stock, with an average rating of Buy; their mean price target of 100.47 USD is 78.1% above the current price. The next earnings report is expected on 18 February 2027.